The COVID-19 pandemic has brought the world literally to a standstill. Council of Scientific and Industrial Research (CSIR), India through its 38 laboratories and expertise in diverse areas ranging from aerospace to buildings to genomics to chemicals, quickly sprang into action developing COVID-19 interventions. CSIR, India's rich R&D knowledgebase is embodied in the rapid testing, cost-effective diagnostic kits, virus culture, genome sequencing and disease surveillance. With the perfect blend of scientific knowledge, technical expertise, industry linkages and governmental interfaces, through innovations and improvisations CSIR, India has come up with many technologies and products to be deployed against COVID-19. The key to flattening the curve in the number of Coronavirus cases is the detection of the infected at the earliest and isolating them. A combination of digital and molecular surveillance with rapid diagnosis is the need and CSIR is striving towards that using multiple strategies.  CSIR, India was one of the first institutions to carry out testing in the country. With state-of the-art genomics and molecular biology laboratories in the CSIR,India network, CSIR,India has not only been at the forefront of testing but also developing cost-effective and accurate diagnostic kits for detecting the COVID-19 virus. One of the many technologies developed by CSIR is FELUDA: FnCas9 Editor Linked Uniform Detection Assay. It is a Paper Based Diagnostic based on CRISPR-Cas. It employs a highly accurate enzymatic readout for detecting nucleotide sequences, identifying nucleobase identity and inferring zygosity with precision. It has Broad reach, simpler, less set up cost, visual detection. It has been Independently Validated and Approved by DCGI, the regulatory authority of India. This technology can also be adopted for other diseases. We eagerly look forward to partnering with R&D organizations and industries from around the world to take this technology to the people.